Literature DB >> 8153405

Systemic lupus erythematosus and pregnancy.

M Petri1.   

Abstract

Although most women with systemic lupus erythematosus can achieve a successful pregnancy, fetal (fetal loss, preterm birth) and maternal (lupus flares, worsening renal function) morbidity remain major problems. Predictors of fetal loss and preterm birth have been identified and are reviewed. Modern management of lupus pregnancy includes identification of high-risk pregnancies with appropriate monitoring and treatment (when indicated) for anti-Ro and antiphospholipid antibodies, frequent assessment of and control of maternal lupus activity, adjustment of medications to avoid those associated with fetal teratogenicity, and the appropriate use of fetal assessment tests to guide intervention for the fetus at risk of intrauterine death.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8153405      PMCID: PMC5288842     

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  69 in total

Review 1.  Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review.

Authors:  Sylwia Kuc; Esther J Wortelboer; Bas B van Rijn; Arie Franx; Gerard H A Visser; Peter C J I Schielen
Journal:  Obstet Gynecol Surv       Date:  2011-04       Impact factor: 2.347

Review 2.  Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.

Authors:  M Empson; M Lassere; J Craig; J Scott
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

3.  Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?

Authors:  Jinoos Yazdany; Laura Trupin; Rachel Kaiser; Gabriela Schmajuk; Joann Zell Gillis; Eliza Chakravarty; Eleanor Bimla Schwarz
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-11-15       Impact factor: 4.794

4.  The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus.

Authors:  Megan E B Clowse; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2011-03-16       Impact factor: 4.666

Review 5.  The clinical spectrum of autoimmune congenital heart block.

Authors:  Pilar Brito-Zerón; Peter M Izmirly; Manuel Ramos-Casals; Jill P Buyon; Munther A Khamashta
Journal:  Nat Rev Rheumatol       Date:  2015-03-24       Impact factor: 20.543

6.  The impact of increased lupus activity on obstetric outcomes.

Authors:  Megan E B Clowse; Laurence S Magder; Frank Witter; Michelle Petri
Journal:  Arthritis Rheum       Date:  2005-02

Review 7.  Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression.

Authors:  Anselm Mak; Mike W-L Cheung; Alicia Ai-cia Cheak; Roger Chun-Man Ho
Journal:  Rheumatology (Oxford)       Date:  2009-12-04       Impact factor: 7.580

8.  Renal biopsy in the management of lupus nephritis during pregnancy.

Authors:  T K Chen; A C Gelber; F R Witter; M Petri; D M Fine
Journal:  Lupus       Date:  2014-09-23       Impact factor: 2.911

Review 9.  Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside.

Authors:  Jill P Buyon; Robert M Clancy; Deborah M Friedman
Journal:  Nat Clin Pract Rheumatol       Date:  2009-03

10.  Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results.

Authors:  Cecile M Yelnik; Carl A Laskin; T Flint Porter; D Ware Branch; Jill P Buyon; Marta M Guerra; Michael D Lockshin; Michelle Petri; Joan T Merrill; Lisa R Sammaritano; Mimi Y Kim; Jane E Salmon
Journal:  Lupus Sci Med       Date:  2016-01-12
View more
  9 in total

Review 1.  Recognition and management of systemic lupus erythematosus.

Authors:  J O Schroeder; H H Euler
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells.

Authors:  Greg Nalbandian; Susan Kovats
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 3.  The safety of antimalarial drugs in pregnancy.

Authors:  P A Phillips-Howard; D Wood
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 4.  A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis.

Authors:  Andrew Smyth; Guilherme H M Oliveira; Brian D Lahr; Kent R Bailey; Suzanne M Norby; Vesna D Garovic
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 8.237

5.  The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014.

Authors:  Elham Rajaei; Nahid Shahbazian; Hadi Rezaeeyan; Amal Kia Mohammadi; Saeed Hesam; Zeinab Deris Zayeri
Journal:  Clin Rheumatol       Date:  2019-07-27       Impact factor: 2.980

6.  Active disease during pregnancy is associated with poor foetal outcome in Indian patients with systemic lupus erythematosus.

Authors:  Vinod Chandran; Amita Aggarwal; Ramnath Misra
Journal:  Rheumatol Int       Date:  2004-12-31       Impact factor: 2.631

Review 7.  Preconception care: screening and management of chronic disease and promoting psychological health.

Authors:  Zohra S Lassi; Ayesha M Imam; Sohni V Dean; Zulfiqar A Bhutta
Journal:  Reprod Health       Date:  2014-09-26       Impact factor: 3.223

8.  Prognosis of neonates in pregnant women with systemic lupus erythematosus.

Authors:  So-Young Kim; Jung-Hyun Lee
Journal:  Yonsei Med J       Date:  2008-08-30       Impact factor: 2.759

9.  Maternal and fetal outcomes of 72 pregnancies in Argentine patients with systemic lupus erythematosus (SLE).

Authors:  Javier A Cavallasca; Hugo A Laborde; Hilda Ruda-Vega; Gustavo G Nasswetter
Journal:  Clin Rheumatol       Date:  2007-05-22       Impact factor: 3.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.